World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
121
Citations
56899
World Ranking
3596
National Ranking
357

David P. Dearnaley publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David P. Dearnaley sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 751 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David P. Dearnaley D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David P. Dearnaley sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 121 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David P. Dearnaley is affiliated with the Institute of Cancer Research in the United Kingdom. Their research primarily focuses on medicine with a significant concentration in pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, oncology, radiation, and surgery.

The scientist has contributed extensively to the study and treatment of prostate cancer, particularly in the areas of prostate cancer treatment and research, prostate cancer diagnosis and treatment, as well as advanced radiotherapy techniques. Additional areas of research include radiopharmaceutical chemistry and applications, bladder and urothelial cancer treatments, statistical methods in clinical trials, and hormonal and reproductive studies.

Frequent publication venues for their work include:

  • Journal of Clinical Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • The Lancet Oncology
  • Radiotherapy and Oncology
  • European Urology

Some of the recent papers authored or co-authored by David P. Dearnaley are:

  • NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer, 2020, International Journal of Radiation Oncology*Biology*Physics
  • Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer, 2021, JAMA Oncology
  • Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial, 2022, PLoS Medicine
  • A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study, 2021, The Lancet Oncology
  • Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol, 2023, The Lancet Oncology

David P. Dearnaley has frequently collaborated with several researchers, including:

  • Emma Hall
  • Matthew R. Sydes
  • Alison Tree
  • Nicholas D. James
  • Isabel Syndikus

Best Publications

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.

    Gillian C. Barnett;Gillian C. Barnett;Charlotte E. Coles;Rebecca M. Elliott;Caroline Baynes

  • Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

    David Dearnaley;Isabel Syndikus;Helen Mossop;Vincent Khoo

  • Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

    Christopher C Parker;Nicholas D James;Christopher D Brawley;Noel W Clarke

  • Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

    Gerhardt Attard;Alison H.M. Reid;Timothy A. Yap;Florence Raynaud

  • Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

    David P Dearnaley;Matthew R Sydes;John D Graham;Edwin G Aird

  • Multiple newly identified loci associated with prostate cancer susceptibility.

    Rosalind A Eeles;Rosalind A Eeles;Zsofia Kote-Jarai;Graham G Giles;Graham G Giles;Ali Amin Al Olama

  • Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial

    David P Dearnaley;Vincent S Khoo;Andrew R Norman;Lesley Meyer

  • Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

    Gerhardt Attard;Alison H.M. Reid;Roger A'Hern;Christopher Parker

  • Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

    Gerhardt Attard;Joost F. Swennenhuis;David Olmos;Alison H.M. Reid

  • Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array

    Rosalind A. Eeles;Ali Amin Al Olama;Sara Benlloch;Edward J. Saunders

  • Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer

    R.A. Huddart;A. Norman;M. Shahidi;A. Horwich

  • Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

    J. M Crook;C. J O'Callaghan;G Duncan;D. P Dearnaley

  • Hormonal impact of the 17 alpha-hydroxylase/C-17,C-20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

    A. O'Donnell;I. Judson;M. Dowsett;F. Raynaud

  • Stereotactic body radiotherapy for oligometastases.

    Alison C Tree;Vincent S Khoo;Rosalind A Eeles;Merina Ahmed

  • Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

    Alison H.M. Reid;Gerhardt Attard;Daniel C. Danila;Nikhil Babu Oommen

  • Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

    Rosalind A. Eeles;Zsofia Kote-Jarai;Ali Amin Al Olama;Graham G. Giles;Graham G. Giles

  • Influence of Cytokine Gene Polymorphisms on the Development of Prostate Cancer

    Sarah L. McCarron;Stephen Edwards;Philip R. Evans;Roz Gibbs

  • Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

    David P Dearnaley;David P Dearnaley;Gordana Jovic;Isabel Syndikus;Vincent Khoo

Frequent Co-Authors

Alan Horwich
Alan Horwich Royal Marsden NHS Foundation Trust
Chris Parker
Chris Parker Institute of Cancer Research
Robert Huddart
Robert Huddart Institute of Cancer Research
Vincent Khoo
Vincent Khoo Royal Marsden NHS Foundation Trust
Rosalind A. Eeles
Rosalind A. Eeles Institute of Cancer Research
Matthew R. Sydes
Matthew R. Sydes University College London
A. R. Norman
A. R. Norman Royal Marsden NHS Foundation Trust
Malcolm David Mason
Malcolm David Mason Cardiff University
Gerhardt Attard
Gerhardt Attard University College London
Nicholas D. James
Nicholas D. James Institute of Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring alternative routes to a medical career or looking to complement your medical studies, there are several online degrees and certifications worth considering. Nursing remains a popular and accessible choice—especially programs that let you build on existing credentials. For those already working as registered nurses, rn to bsn online programs offer a convenient way to earn a Bachelor of Science in Nursing from home.

If you hold a non-nursing bachelor’s degree and wish to enter the nursing profession rapidly, direct entry msn programs online can be an excellent fast-track option. For those seeking accessible entry points into nursing, you may want to explore what is the easiest nursing program to get into for more information on programs with flexible admission requirements.

Beyond direct patient care, there are also administrative career paths. For example, you can earn a certification in online medical billing and coding with financial aid, enabling you to work in hospitals, clinics, or insurance companies. These related fields offer versatility and the potential for career advancement within healthcare.

Best Scientists Citing David P. Dearnaley

Trending Scientists

Recently Published Articles